Topic Name

Message

If ARUP Consult does not answer your test selection and interpretation questions, or if you would like to suggest ways to improve content or usability, please send a message to the Consult editorial staff.

Please do not include any patient-specific or personal health information (PHI) in your message.

Email Address

An email address is not required, but providing one allows the ARUP Consult editorial staff to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use.

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Atherosclerotic Cardiovascular Disease (ASCVD) Apolipoprotein B, B/A Ratio

0020421

Lipid Panel 0020421

0050028

Apolipoprotein B/A Ratio 0050028

0050182

C-Reactive Protein, High Sensitivity 0050182

3002266

Lp-PLA2, Lipoprotein-Associated Phospholipase A2, Activity (PLAC) 3002266

About This Topic

There is insufficient evidence to recommend or discourage the use of certain nontraditional markers in asymptomatic adults. Apolipoprotein B/A Ratio (0050028) biomarker testing may be considered for intermediate- to high-risk patient subgroups as identified from the initial screening.

Recommendation

A fasting Lipid Panel (0020421) with total cholesterol, triglycerides, LDL, and HDL should be used for screening.

C-Reactive Protein, High Sensitivity (0050182) and Lp-PLA2, Lipoprotein-Associated Phospholipase A2, Activity (PLAC) (3002266) may aid in CVD risk stratification in specific populations.

ARUP Consult

Recommending Body

Feedback

Atherosclerotic Cardiovascular Disease (ASCVD) Apolipoprotein B, B/A Ratio

24222018

28437620

24222016